Posters
Efficacy and safety of the ab interno gelatin stent in severe pseudoexfoliation glaucoma compared to non-pseudoexfoliation glaucoma at 6 months
Poster Details
First Author: N.Dar ISRAEL
Co Author(s): T. Sharon I. Hecht Z. Burgansky-Eliash
Abstract Details
Purpose:
To compare the efficacy and safety of the XEN 45 gel stent surgery between patients with and without severe pseudoexfoliation glaucoma (PXFG).
Setting:
All operations conducted at the Edith Wolfson Medical Center in Holon, Israel between October 2016 and January 2018
Methods:
In this retrospective, single centre, comparative chart review, records of 24 eyes of 23 patients with PXFG and 24 eyes of 23 patients with non-PXFG with severe glaucoma, defined as uncontrolled intraocular pressure (IOP) on maximally tolerated medical therapy, were reviewed. All patients were treated with XEN 45 gel stent surgery, in either a standalone procedure (84.8%) or combined with phacoemulsification (15.2%). Mean IOP, mean number of IOP-lowering medications, change in best-corrected visual acuity and needling or rescue surgery rates were assessed. Success was defined as at least 20% decrease in baseline IOP among treatment-free patients.
Results:
Patient characteristics were similar between groups. At 6 months, IOP in the PXFG group decreased by 32% (24.3±9 mmHg to 14.8±7 mmHg, P<0.001), with comparable decrease in IOP in the non-PXFG group (22.6±7mmHg to 16.7±6mmHg, P=0.011). However, IOP decreased more in the PXFG group among treatment-free patients (-10.1±8.0 mmHg vs -4.1±8.1 mmHg, P=0.043) and final IOP was lower in the PXFG group (12.2±3.5 mmHg vs 15.8±5.7mmHg, respectively. P=0.044). Mean failure-free survival in PXFG patients was 5.2±0.5 months (95%CI: 4.2-6.1) vs 4.3±0.6 months (95%CI: 3.1-5.5) in non-PXFG patients (P=0.062).
Conclusions:
The XEN45 Gel Stent implant demonstrated similar efficacy and safety among severe PXFG and non-PXFG patients. Greater magnitude of decreased IOP occurred among treatment-free PXFG patients.
Financial Disclosure:
None
